No Data
*ST Pharmaceuticals: Dali Pharmaceutical Co., Ltd. 2024 Annual Results Advance Loss Announcement
Dali Pharmaceutical Co., Ltd. 2024 Annual Results Advance Loss Announcement
On January 10, A-share investment warning signals︱*Special Treat Jiayu: Stocks may be delisted; Shanghai Smith Adhesive New Material: Currently not involved in "liquid Metal cooling materials."
Dali Cape's shareholder Panxin Investment plans to reduce its shareholding by no more than 4.50%; Zhejiang Shuanghuan Driveline's shareholders Li Shaoguang and Li Yu plan to collectively reduce their holdings by no more than 8 million shares; Anjies shareholders Xinjianyuan and Paradise Silicon Valley plan to collectively reduce their shareholding by no more than 3%; *ST Jiayu's stocks may be delisted; Shanghai Hi-tech Control System stated that its greening business includes high-power electrical utilities and new energy storage business; Shenzhen Hopewind Electric stated that there are no related orders for datacenter business, not involving datacenter hotspots; *ST Dayao company's stocks may be delisted; Shanghai Smith Adhesive New Material is currently not involved in "liquid metal cooling materials."
*Special Treat Pharmaceutical (603963.SH): The company's Stocks may be delisted.
*ST Dayao (603963.SH) announced on January 9 that according to the disclosed "2024 Annual Performance Pre-loss Announcement", the company expects that the total profit, Net income, and Net income after deducting non-recurring gains and losses for the year 2024 will all be negative. Additionally, the revenue after deducting business income unrelated to the main Business and income lacking commercial substance will be less than 0.3 billion yuan. After the disclosure of the 2024 annual report, the company’s Stocks may be delisted by the Shanghai Exchange.
*Special Treat Pharmaceuticals (603963.SH): An annual forecast loss of 30 million to 36 million yuan for 2024.
*ST Dayao (603963.SH) announced a pre-loss notice for its 2024 annual performance on January 9. According to preliminary calculations by the financial department, the company expects a total profit for the year 2024 to be between -26 million yuan and -32 million yuan, and the net income attributable to the shareholders of the parent company to be between -30 million yuan and -36 million yuan. The net income attributable to the shareholders of the parent company, after excluding non-recurring gains and losses, is expected to be between -32 million yuan and -39 million yuan. The expected revenue for the year 2024 is between 62 million yuan and 7,400 million yuan.
*ST Big Pharma (603963.SH): There has been no significant change in the main business direction, but there is a risk of being (Delisted) due to financial reasons.
*ST Da Pharmaceutical (603963.SH) announced that the company's Stocks trading price has recently fluctuated significantly. The company's main Business...
